143 related articles for article (PubMed ID: 38116795)
21. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma.
Jung TS; Kim TY; Kim KW; Oh YL; Park DJ; Cho BY; Shong YK; Kim WB; Park YJ; Jung JH; Chung JH
Endocr J; 2007 Apr; 54(2):265-74. PubMed ID: 17379963
[TBL] [Abstract][Full Text] [Related]
22. Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy.
Burningham AR; Krishnan J; Davidson BJ; Ringel MD; Burman KD
Otolaryngol Head Neck Surg; 2005 Jun; 132(6):840-4. PubMed ID: 15944551
[TBL] [Abstract][Full Text] [Related]
23. Intrabony mandibular metastases caused by papillary thyroid carcinoma masquerading as a parotid swelling.
Wareing J; Dawoud B; Power A; Sutton D
Ann R Coll Surg Engl; 2021 Sep; 103(8):e264-e265. PubMed ID: 34464554
[TBL] [Abstract][Full Text] [Related]
24. [Draft of the best medical treatment in patients with low-risk thyroid cancer].
Vlček P; Nováková D; Vejvalka J; Zimák J; Křenek M; Vošmiková K; Smutný S; Bavor P; Astl J; Lukáš J
Vnitr Lek; 2015 Sep; 61(9):769-77. PubMed ID: 26465275
[TBL] [Abstract][Full Text] [Related]
25. Papillary and follicular thyroid cancer: selective therapy.
Mazzaferri EL
Compr Ther; 1981 May; 7(5):6-14. PubMed ID: 7016424
[TBL] [Abstract][Full Text] [Related]
26. Assessment of risk factors in metastatic/recurrent tall cell variant of papillary thyroid carcinoma.
Okuyucu K; Alagoz E; Ince S; Arslan N
Endokrynol Pol; 2017; 68(6):623-630. PubMed ID: 29022644
[TBL] [Abstract][Full Text] [Related]
27. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital.
Mendoza ES; Lopez AA; Valdez VA; Cunanan EC; Matawaran BJ; Kho SA; Sero-Gomez MH
J Endocrinol Invest; 2016 Jan; 39(1):55-62. PubMed ID: 26036600
[TBL] [Abstract][Full Text] [Related]
28. Well differentiated thyroid cancer.
Kinder BK
Curr Opin Oncol; 2003 Jan; 15(1):71-7. PubMed ID: 12490765
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Epidemiology and Long-Term Outcomes in a Strictly Defined Cohort.
Chung R; Guan H; Ponchiardi C; Cerda S; Marwaha N; Yilmaz OH; Pinjic E; McAneny D; Lee SL; Drake FT
Thyroid; 2021 Jan; 31(1):68-75. PubMed ID: 32539676
[No Abstract] [Full Text] [Related]
30. Management of invasive and advanced thyroid cancer.
Favia G; Iacobone M; Zanella S; Ciarleglio FA
Minerva Endocrinol; 2009 Mar; 34(1):37-55. PubMed ID: 19209127
[TBL] [Abstract][Full Text] [Related]
31. Assessment of recurrence rates in papillary thyroid microcarcinoma patients with and without histopathological risk factors after radioiodine ablation treatment.
Soydal C; Araz M; Ozkan E; Arslantaş E; Kucuk ON; Aras G
Nucl Med Commun; 2015 Feb; 36(2):109-13. PubMed ID: 25321158
[TBL] [Abstract][Full Text] [Related]
32. Tall cell variant papillary thyroid carcinoma impacts disease-free survival at the 10 % cut-point on multivariate analysis.
Samankan S; Militello L; Seo G; Everest S; O'Malley Q; Spaulding SL; Xing M; Matloob A; Beute J; Chai R; Doyle S; Urken ML; Brandwein-Weber M
Pathol Res Pract; 2022 Aug; 236():154012. PubMed ID: 35834884
[TBL] [Abstract][Full Text] [Related]
33. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group.
Hölzer S; Reiners C; Mann K; Bamberg M; Rothmund M; Dudeck J; Stewart AK; Hundahl SA
Cancer; 2000 Jul; 89(1):192-201. PubMed ID: 10897018
[TBL] [Abstract][Full Text] [Related]
34. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
Song E; Jeon MJ; Oh HS; Han M; Lee YM; Kim TY; Chung KW; Kim WB; Shong YK; Song DE; Kim WG
Eur J Endocrinol; 2018 Sep; 179(3):135-142. PubMed ID: 29875289
[TBL] [Abstract][Full Text] [Related]
35. Improving postoperative recurrence rates for carcinoma of the thyroid gland.
McHenry C; Jarosz H; Lawrence AM; Paloyan E
Surg Gynecol Obstet; 1989 Nov; 169(5):429-34. PubMed ID: 2814754
[TBL] [Abstract][Full Text] [Related]
36. [Papillary cancer of the thyroid: biological behaviour and therapeutic planning (author's transl)].
Spreafico G; Colombo L; Puricelli G
Radiol Med; 1978 Sep; 64(9):1005-20. PubMed ID: 749025
[TBL] [Abstract][Full Text] [Related]
37. Low risk papillary thyroid cancer.
Brito JP; Hay ID; Morris JC
BMJ; 2014 Jun; 348():g3045. PubMed ID: 24935445
[TBL] [Abstract][Full Text] [Related]
38. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
39. Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea.
Yoon JH; Jeon MJ; Kim M; Hong AR; Kim HK; Shin DY; Kim BH; Kim WB; Shong YK; Kang HC
PLoS One; 2020; 15(8):e0238207. PubMed ID: 32841270
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma.
Wu X; Gu H; Gao Y; Li B; Fan R
Nucl Med Commun; 2018 Jan; 39(1):22-27. PubMed ID: 29135721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
